Success Stories: EB-1B Approval After RFE Achieved by NAILG for Scientist Transforming Cell-Based Therapeutic Research

Client’s Testimonial:

“Thank you very much for your help.”

On October 20^th, 2025, we received another EB-1B (Outstanding Professors and Researchers) approval for a Research Fellow (Postdoctoral) in the Field of Cell Biology (Approval Notice).

General Field: Cell Biology

Position at the Time of Case Filing: Research Fellow (Postdoctoral)

Country of Origin: China

State of Residence at the Time of Filing: Massachusetts

Approval Notice Date: October 20^th, 2025

Processing Time: 1 year, 6 months, 12 days

Case Summary:

An EB-1B (Outstanding Researcher) petition was approved for a cell biology expert whose groundbreaking work in molecular imaging and immunotherapy has made lasting contributions to biomedical science. The petition, filed on April 8, 2024, received a Request for Evidence (RFE) on September 3, 2025, and was approved on October 20, 2025, after North America Immigration Law Group (NAILG) presented a detailed and compelling response that clearly demonstrated the petitioner’s record of sustained international recognition and research excellence.

The petitioner’s research bridges cell biology, molecular biochemistry, and immuno-oncology. His work focuses on developing biosensors for real-time cell imaging, investigating metabolic regulation in immune responses, and designing innovative therapeutic strategies for cancer treatment. Through this multifaceted approach, he has advanced the understanding of cellular dynamics, immune regulation, and tumor microenvironments, areas crucial to improving the diagnosis and treatment of complex diseases. His pioneering methods have been recognized by peers for their originality and far-reaching clinical implications.

Over the course of his career, the petitioner has published 14 peer-reviewed journal articles, including five first- or co-first-authored papers, which have collectively been cited 655 times by independent researchers worldwide. His studies have appeared in highly selective journals, reflecting both the quality and influence of his work. His research has become a foundation for further developments in metabolic pathway analysis and cell-based therapies, underscoring its substantial and ongoing impact.

In addition to his publication record, the petitioner has completed at least 25 peer reviews for leading international journals, further demonstrating his expertise and professional standing. His participation as a reviewer confirms that he is recognized by the global scientific community as a trusted authority capable of assessing complex research in cell biology, molecular therapy, and cancer immunology. This ongoing engagement with high-impact publications reflects both his leadership and his commitment to advancing scientific integrity and innovation.

NAILG’s strategic RFE response emphasized the petitioner’s sustained record of achievement, international influence, and major contributions to cancer biology and therapeutic development. By presenting comprehensive evidence of his scholarly impact, leadership in peer review, and influence on ongoing research worldwide, NAILG successfully established that he meets the rigorous standards for EB-1B classification. The petition’s approval reaffirms his position among the foremost researchers in his field and highlights NAILG’s continued success in securing immigration benefits for world-class scientists driving advances in biomedical innovation.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.